acanthosis nigricans
MONDO:0007035
A melanotic cutaneous lesion that develops in the axilla and other body folds. It may be idiopathic, drug-induced, or it may be associated with the presence of an endocrine disorder or malignancy.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Acanthosis nigricans
Acanthosis nigricans is a cutaneous finding characterized by brown-to-black, velvety hyperpigmentation of the skin, most often affecting body folds such as the posterior neck, axillae, groin and umbilicus. It is strongly associated with insulin resistance and hyperinsulinaemia, including in type 2 diabetes and metabolic syndrome. Excess insulin activates insulin and insulin-like growth factor signalling pathways, stimulating proliferation of keratinocytes and fibroblasts and producing the characteristic plaques. Acanthosis nigricans may also occur in hereditary syndromes, as a reaction to medications, or as a paraneoplastic syndrome associated with internal malignancy. In children, it is an important clinical marker of metabolic and cardiometabolic risk.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
5 shownDrugs being studied
Research locations
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.